By 
                  Liz Highleyman
                  
                   Most 
                  experts estimate that approximately one-quarter to one-third 
                  of people initially infected with HCV will naturally clear the 
                  virus without treatment thanks to an effective immune response. 
                  Among those with persistent infection, however, HCV can over 
                  years or decades cause serious liver disease including cirrhosis 
                  and hepatocellular 
                  carcinoma, a form of primary liver cancer.
Most 
                  experts estimate that approximately one-quarter to one-third 
                  of people initially infected with HCV will naturally clear the 
                  virus without treatment thanks to an effective immune response. 
                  Among those with persistent infection, however, HCV can over 
                  years or decades cause serious liver disease including cirrhosis 
                  and hepatocellular 
                  carcinoma, a form of primary liver cancer. 
                Research 
                  has shown that people with chronic 
                  hepatitis C have a higher risk of liver-related death, but 
                  outcomes among people who were once infected but naturally cleared 
                  the virus have not been extensively studied.
                  
                  In the present analysis, Lars Haukali Omland and fellow investigators 
                  with the DANVIR Cohort Study examined the association between 
                  chronic HCV replication and mortality among Danish patients 
                  who tested positive for HCV antibodies.
                  
                  This nationwide cohort study looked at more than 6000 patients 
                  with at least 1 HCV RNA (genetic material) viral load measurement 
                  available after testing positive for HCV antibodies between 
                  1996 and 2005. To capture long-term outcomes, eligible participants 
                  needed to be alive for at least 1 year after HCV RNA assessment. 
                  
                  
                  The researchers estimated mortality rate ratios (MRRs) for overall 
                  mortality and sub-distribution hazard ratios (SDHRs) for cause-specific 
                  mortality, after controlling for patient sex, age, co-existing 
                  conditions, heavy alcohol use, injection drug use, and income. 
                  
                  
                   Results 
                  
                
                   
                    |  | Of 
                      the 6292 patients in the study, 37% spontaneously cleared 
                      HCV, while 63% developed chronic infection. | 
                   
                    |  | Overall 
                      5-year survival rates were 92% for participants who cleared 
                      the virus, compared with 86% for those with chronic infection. | 
                   
                    |  | Chronic 
                      HCV infection was associated with higher overall mortality 
                      compared with viral clearance (MRR 1.55). | 
                   
                    |  | Chronic 
                      infection was also associated with a more than a 2-fold 
                      greater risk of liver-related death (SDHR 2.42). | 
                   
                    |  | In 
                      particular, chronic HCV infection greatly increased -- by 
                      more than 16-fold -- the risk of death due to primary liver 
                      cancer (SDHR 16.47). | 
                
                Based 
                  on these findings, the study authors concluded, "Patients 
                  with chronic HCV infection are at higher risk of death than 
                  patients who cleared the infection." 
                  
                  "The substantial association found between chronic HCV 
                  infection and death from primary liver cancer supports early 
                  initiation of antiviral treatment in chronically HCV-infected 
                  patients," they recommended.
                  
                  Investigator affiliations: Department of Infectious Diseases, 
                  Rigshospitalet, Copenhagen; Department of Clinical Biochemistry, 
                  Aalborg Hospital; Department of Clinical Epidemiology, Aarhus 
                  University Hospital; Department of Clinical Immunology, Odense 
                  University Hospital; Department of Clinical Immunology and Blood 
                  Bank, Rigshospitalet, Copenhagen; Department of Clinical Immunology, 
                  Viborg Region Hospital; Department of Clinical Immunology, Hospital 
                  of Southern Jutland, Region of Southern Denmark; Department 
                  of Clinical Microbiology, Vejle Hospital; Department of Infectious 
                  Diseases, Odense University Hospital, Denmark; Department of 
                  Epidemiology, Boston University School of Public Health, Boston, 
                  MA.
                  
                  8/31/10
                Reference
                  LH 
                  Omland, H Krarup, P Jepsen, and others (DANVIR Cohort Study). 
                  Mortality in patients with chronic and cleared hepatitis C viral 
                  infection: a nationwide cohort study. Journal of Hepatology 
                  53(1): 36-42 (Abstract). 
                  July 2010.